BGIM
PTCT icon

Brandywine Global Investment Management’s PTC Therapeutics PTCT Stock Holding History

Brandywine Global Investment Management’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-1
Closed -$1K – 944
2017
Q4 		$1K Hold
1
– – ﹤0.01% 873
2017
Q3 		$1K Hold
1
– – ﹤0.01% 868
2017
Q2 		$1K Hold
1
– – ﹤0.01% 882
2017
Q1 		$1K Hold
1
– – ﹤0.01% 910
2016
Q4 		$1K Hold
1
– – ﹤0.01% 919
2016
Q3 		$1K Sell
1
-56,850
-100% -$462K ﹤0.01% 926
2016
Q2 		$400K Sell
56,851
-34,940
-38% -$256K ﹤0.01% 629
2016
Q1 		$592K Sell
91,791
-631,030
-87% -$11M ﹤0.01% 594
2015
Q4 		$23.4M Buy
722,821
+46,572
+7% +$1.37M 0.15% 130
2015
Q3 		$18.1M Sell
676,249
-25,237
-4% -$1.08M 0.12% 157
2015
Q2 		$33.8M Buy
701,486
+131,911
+23% +$7.7M 0.21% 100
2015
Q1 		$34.7M Buy
+569,575
New +$34.8M 0.22% 96

Other funds holding PTCT

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Brandywine Global Investment Management's PTCT Position: Q1 2018 in Review

Brandywine Global Investment Management sold out of PTC Therapeutics (PTCT) in Q1 2018, closing a stake of 1 share — an estimated $1K sold.

Brandywine Global Investment Management first reported a position in PTCT in Q1 2015 and held it in 12 quarters. The position peaked at $34.7M in Q1 2015. 148 funds tracked by Wall St. Rank hold PTCT as of Q1 2018.

  • Brandywine Global Investment Management reported no remaining PTC Therapeutics position as of Q1 2018 after selling out during the quarter.
  • Brandywine Global Investment Management sold 1 PTC Therapeutics share in Q1 2018, an estimated $1K.
  • Brandywine Global Investment Management first reported a position in PTC Therapeutics in Q1 2015 and held it in 12 quarters.
  • Brandywine Global Investment Management's PTC Therapeutics position peaked at $34.7M in Q1 2015.
  • 148 funds tracked by Wall St. Rank held PTC Therapeutics as of Q1 2018.

Based on Brandywine Global Investment Management's 13F filing for Q1 2018, filed 15 May 2018.